TNFRSF18 and neoplasm: Preclinical evidence demonstrates that a combined anti-PD-1/GITR treatment with 250 μg of each compound, when administered intraperitoneally, significantly inhibited tumor growth in tumor-bearing mice compared to either compound in monotherapy [91].